CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:CBAY
- CUSIP: N/A
- Web: www.cymabay.com
- Market Cap: $282.23 million
- Outstanding Shares: 43,756,000
- 50 Day Moving Avg: $6.64
- 200 Day Moving Avg: $4.54
- 52 Week Range: $1.15 - $8.29
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.92
- P/E Growth: 0.00
- Annual Revenue: $4.79 million
- Price / Sales: 58.92
- Book Value: $0.07 per share
- Price / Book: 92.14
- EBIDTA: ($20,290,000.00)
- Return on Equity: -425.44%
- Return on Assets: -122.91%
- Debt-to-Equity Ratio: 2.15%
- Current Ratio: 1.49%
- Quick Ratio: 1.49%
- Average Volume: 1.06 million shs.
- Beta: 2.11
- Short Ratio: 0.5
Frequently Asked Questions for CymaBay Therapeutics (NASDAQ:CBAY)
What is CymaBay Therapeutics' stock symbol?
CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."
How were CymaBay Therapeutics' earnings last quarter?
CymaBay Therapeutics Inc. (NASDAQ:CBAY) released its earnings results on Thursday, August, 10th. The company reported ($0.31) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.06. View CymaBay Therapeutics' Earnings History.
When will CymaBay Therapeutics make its next earnings announcement?
Where is CymaBay Therapeutics' stock going? Where will CymaBay Therapeutics' stock price be in 2017?
7 brokerages have issued 1 year target prices for CymaBay Therapeutics' stock. Their predictions range from $12.00 to $15.00. On average, they expect CymaBay Therapeutics' stock price to reach $14.00 in the next twelve months. View Analyst Ratings for CymaBay Therapeutics.
What are analysts saying about CymaBay Therapeutics stock?
Here are some recent quotes from research analysts about CymaBay Therapeutics stock:
- 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (4/3/2017)
- 2. HC Wainwright analysts commented, " Recall, on December 7, CymaBay initiated an open-label, dose-ranging Phase 2 study (NCT02955602) of seladelpar (MBX-8025) in about 36 patients with primary biliary cholangitis (PBC) who are not adequately responding to, or are intolerant of, ursodeoxycholic acid (UCDA). Notably, the study sites are located in U.S., Canada, Germany and the U.K. Per protocol, patients are randomized to either 5 mg or 10 mg for 8 weeks. Based on review of the safety and efficacy of the 8 week data, new patients are then enrolled to receive 25 mg of seladelpar for 8 weeks. We also point out that the study incorporates an extension phase where patients are able to continue treatment for a total of 26 weeks, thus allowing for dose adjustments. In this trial, the primary endpoint is the reduction of alkaline phosphate (ALP) from baseline. Preliminary results from the first two cohorts (5 mg and 10 mg) are expected in early 3Q17 (likely July), with data readout of the third cohort (25 mg) anticipated by year end. Ahead of this important, near-term value inflection, we affirm our Buy rating on CBAY shares and raise our price target to $7." (3/27/2017)
- 3. Piper Jaffray Companies analysts commented, "CymaBay ended 2016 with cash of $17 million, and subsequently CymaBay received $5 million upfront from Kowa in January and raised net proceeds of $9.2 million in February bringing pro forma cash to ~$31 million. CymaBay will report Phase II data on 5mg and 10mg seladelpar in primary biliary cholangitis (PBC) in 3Q:17 followed by 25mg seladelpar data in 4Q:17. We will look for ALP reduction with enhanced liver safety following 3 transaminase elevations at higher doses in the prior study. Encouraging preclinical data for seladelpar in NASH could lead to a pre-IND meeting with the FDA in 2Q:17. CymaBay has partnered Phase III-ready arhalophenate with Kowa in the U.S., and could partner in Europe. We reiterate our Overweight rating and are increasing our price target to $6.50 from $5 by adding value for seladelpar in NASH." (3/24/2017)
Are investors shorting CymaBay Therapeutics?
CymaBay Therapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 1,076,152 shares, an increase of 75.9% from the July 14th total of 611,816 shares. Based on an average daily volume of 3,069,062 shares, the days-to-cover ratio is presently 0.4 days. Currently, 2.7% of the shares of the company are sold short.
Who are some of CymaBay Therapeutics' key competitors?
Some companies that are related to CymaBay Therapeutics include Paratek Pharmaceuticals (PRTK), Ignyta (RXDX), Calithera Biosciences (CALA), Seres Therapeutics (MCRB), Audentes Therapeutics (BOLD), CytomX Therapeutics (CTMX), Sucampo Pharmaceuticals (SCMP), Aurinia Pharmaceuticals (AUPH), Intra-Cellular Therapies (ITCI), Jounce Therapeutics (JNCE), AnaptysBio (ANAB), NantKwest (NK), Atara Biotherapeutics (ATRA), Progenics Pharmaceuticals (PGNX), AVEO Pharmaceuticals (AVEO), Karyopharm Therapeutics (KPTI), Mersana Therpts (MRSN) and BioCryst Pharmaceuticals (BCRX).
Who are CymaBay Therapeutics' key executives?
CymaBay Therapeutics' management team includes the folowing people:
- Robert James Wills Ph.D., Chairman of the Board
- Sujal Shah, Interim President, Interim Chief Executive Officer, Chief Financial Officer
- Charles A. McWherter Ph.D, Senior Vice President, Chief Scientific Officer
- Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer
- Kirk Rosemark, Vice President - Regulatory Affairs and Quality Assurance
- Pol F. Boudes M.D., Chief Medical Officer
- Robert Booth Ph.D., Director
- Caroline Loewy, Director
- Evan A. Stein M.D. Ph.D., Director
- Paul F. Truex, Director
Who owns CymaBay Therapeutics stock?
CymaBay Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Versant Venture Management LLC (3.65%), Vanguard Group Inc. (3.45%), Omega Fund Management LLC (1.05%), Northern Trust Corp (0.18%), Marshall Wace North America L.P. (0.14%) and Alpha Cubed Investments LLC (0.07%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Robert James Wills and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.
Who sold CymaBay Therapeutics stock? Who is selling CymaBay Therapeutics stock?
Who bought CymaBay Therapeutics stock? Who is buying CymaBay Therapeutics stock?
CymaBay Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Marshall Wace North America L.P., LVM Capital Management Ltd. MI and Bank of New York Mellon Corp. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Robert James Wills and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.
How do I buy CymaBay Therapeutics stock?
Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CymaBay Therapeutics' stock price today?
MarketBeat Community Rating for CymaBay Therapeutics (NASDAQ CBAY)MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of CymaBay Therapeutics stock can currently be purchased for approximately $6.45.
Consensus Ratings for CymaBay Therapeutics (NASDAQ:CBAY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||7 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$14.00 (117.05% upside)|
Analysts' Ratings History for CymaBay Therapeutics (NASDAQ:CBAY)
(Data available from 8/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/18/2017||SunTrust Banks, Inc.||Initiated Coverage||Buy -> Buy||$15.00||High|
|8/11/2017||Ifs Securities||Downgrade||Strong-Buy -> Outperform||High|
|7/25/2017||Piper Jaffray Companies||Reiterated Rating||Positive -> Overweight||$12.00||Low|
|7/20/2017||CIBC||Reiterated Rating||Outperform -> Outperform||$8.00 -> $15.00||Medium|
|7/20/2017||Oppenheimer Holdings, Inc.||Boost Price Target||Outperform||$8.00 -> $15.00||Medium|
|7/20/2017||Citigroup Inc.||Reiterated Rating||Outperform||$8.00 -> $15.00||Medium|
|7/17/2017||HC Wainwright||Boost Price Target||Buy||$7.00 -> $12.00||High|
|7/1/2016||Roth Capital||Initiated Coverage||Buy||N/A|
Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)Earnings History by Quarter for CymaBay Therapeutics (NASDAQ CBAY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/11/2017||Q1 2017||($0.27)||($0.20)||$4.79 million||View||N/A|
Earnings Estimates for CymaBay Therapeutics (NASDAQ:CBAY)
2017 EPS Consensus Estimate: ($0.81)
2018 EPS Consensus Estimate: $0.28
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for CymaBay Therapeutics (NASDAQ:CBAY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for CymaBay Therapeutics (NASDAQ:CBAY)
Insider Ownership Percentage: 15.10%Insider Trades by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Institutional Ownership Percentage: 25.39%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/1/2017||Robert James Wills||Director||Buy||5,000||$6.84||$34,200.00|| |
|7/20/2017||Charles Mcwherter||SVP||Buy||5,000||$7.43||$37,150.00|| |
|7/20/2017||Sujal Shah||Insider||Buy||10,000||$7.34||$73,400.00|| |
|9/6/2016||Robert James Wills||Director||Buy||25,000||$2.43||$60,750.00|| |
|4/15/2016||Charles Mcwherter||VP||Buy||3,000||$1.68||$5,040.00|| |
|4/5/2016||Sujal Shah||CFO||Buy||55,000||$1.39||$76,450.00|| |
|4/4/2016||Sujal Shah||CFO||Buy||22,000||$1.39||$30,580.00|| |
|9/11/2015||Carl Goldfischer||Director||Sell||46,729||$2.74||$128,037.46|| |
|8/14/2015||Emster Kurt Von||Director||Buy||90,000||$2.69||$242,100.00|| |
|7/20/2015||Emster Kurt Von||Director||Buy||1,600,000||$2.81||$4,496,000.00|| |
|5/18/2015||Sujal Shah||CFO||Buy||10,000||$3.40||$34,000.00|| |
|5/18/2015||Wart Harold Van||CEO||Buy||7,500||$3.34||$25,050.00|| |
|5/15/2015||Charles Mcwherter||VP||Buy||2,000||$3.16||$6,320.00|| |
Headline Trends for CymaBay Therapeutics (NASDAQ:CBAY)
Latest Headlines for CymaBay Therapeutics (NASDAQ:CBAY)
|CymaBay Therapeutics (CBAY) and Bellicum Pharmaceuticals (BLCM) Head-To-Head Survey|
www.americanbankingnews.com - August 20 at 6:20 AM
|CymaBay Therapeutics Inc. (CBAY) Receives New Coverage from Analysts at SunTrust Banks, Inc.|
www.americanbankingnews.com - August 18 at 8:12 AM
|CymaBay Therapeutics (CBAY) Announces the Publication of ... - StreetInsider.com|
www.streetinsider.com - August 16 at 5:29 PM
|CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology|
finance.yahoo.com - August 15 at 5:43 PM
|Analysts Offer Predictions for CymaBay Therapeutics Inc.'s Q4 2017 Earnings (NASDAQ:CBAY)|
www.americanbankingnews.com - August 14 at 6:42 AM
|CymaBay Therapeutics Inc. (CBAY) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - August 14 at 2:44 AM
|Short Interest in CymaBay Therapeutics Inc. (NASDAQ:CBAY) Increases By 75.9%|
www.americanbankingnews.com - August 13 at 1:46 AM
|CymaBay Therapeutics Inc. (NASDAQ:CBAY) Downgraded by Ifs Securities to Outperform|
www.americanbankingnews.com - August 11 at 1:26 PM
|CymaBay Therapeutics Inc. (CBAY) Announces Earnings Results|
www.americanbankingnews.com - August 10 at 9:34 PM
|After-Hours Earnings Report for August 10, 2017 : NVDA, JWN, PBR, NWSA, AZPN, AVXS, PCTY, LXFT, EPAY, NH ... - Nasdaq|
www.nasdaq.com - August 10 at 6:07 PM
|Why CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season - Yahoo Finance|
finance.yahoo.com - August 10 at 6:07 PM
|CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update|
finance.yahoo.com - August 10 at 6:07 PM
|Why CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season - Nasdaq|
www.nasdaq.com - August 9 at 10:11 PM
|Why CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season|
finance.yahoo.com - August 9 at 5:08 PM
|CymaBay Therapeutics Inc. (CBAY) Expected to Announce Earnings of -$0.25 Per Share|
www.americanbankingnews.com - August 9 at 7:46 AM
|CymaBay Therapeutics Inc. (CBAY) Set to Announce Quarterly Earnings on Thursday|
www.americanbankingnews.com - August 8 at 10:44 AM
|Head to Head Review: CymaBay Therapeutics (NASDAQ:CBAY) versus REGENXBIO (RGNX)|
www.americanbankingnews.com - August 8 at 8:30 AM
|CymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10 - GlobeNewswire (press release)|
globenewswire.com - August 7 at 10:27 PM
|CymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10|
finance.yahoo.com - August 7 at 5:26 PM
|CymaBay Therapeutics Inc. (NASDAQ:CBAY) Director Robert James Wills Purchases 5,000 Shares|
www.americanbankingnews.com - August 2 at 10:28 AM
|CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to ... - GlobeNewswire (press release)|
globenewswire.com - July 24 at 4:30 PM
|CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares|
finance.yahoo.com - July 24 at 4:30 PM
|Charles Mcwherter Buys 5,000 Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) Stock|
www.americanbankingnews.com - July 24 at 9:11 AM
|CymaBay Therapeutics Inc. (CBAY) Insider Acquires $73,400.00 in Stock|
www.americanbankingnews.com - July 24 at 9:11 AM
|Q3 2017 EPS Estimates for CymaBay Therapeutics Inc. Raised by Analyst (CBAY)|
www.americanbankingnews.com - July 24 at 7:42 AM
|Equities Analysts Offer Predictions for CymaBay Therapeutics Inc.'s Q4 2017 Earnings (NASDAQ:CBAY)|
www.americanbankingnews.com - July 21 at 1:19 PM
|Citigroup Inc. Reiterates Outperform Rating for CymaBay Therapeutics Inc. (CBAY)|
www.americanbankingnews.com - July 20 at 8:23 PM
|CIBC Reaffirms Outperform Rating for CymaBay Therapeutics Inc. (NASDAQ:CBAY)|
www.americanbankingnews.com - July 20 at 7:08 PM
|Cymabay Therapeutics (CBAY) Catches Eye: Stock Gains 6.2% - Nasdaq|
www.nasdaq.com - July 20 at 6:41 PM
|Cymabay Therapeutics (CBAY) Catches Eye: Stock Gains 6.2%|
finance.yahoo.com - July 20 at 6:41 PM
|CymaBay Therapeutics Inc. (NASDAQ:CBAY) PT Raised to $15.00 at Oppenheimer Holdings, Inc.|
www.americanbankingnews.com - July 20 at 10:50 AM
| Analysts Anticipate CymaBay Therapeutics Inc. (NASDAQ:CBAY) Will Announce Earnings of -$0.25 Per Share|
www.americanbankingnews.com - July 20 at 9:14 AM
|CymaBay Therapeutics Inc. (NASDAQ:CBAY) Given Average Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - July 20 at 9:06 AM
|CymaBay Therapeutics Inc. (NASDAQ:CBAY) Stock Rating Reaffirmed by Ifs Securities|
www.americanbankingnews.com - July 20 at 7:50 AM
|Oppenheimer Bullish on Bank of America Corp (BAC), CymaBay Therapeutics Inc (CBAY) and TherapeuticsMD Inc (TXMD); Here’s Why|
finance.yahoo.com - July 19 at 6:05 PM
|CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis|
finance.yahoo.com - July 19 at 4:31 AM
|H.C. Wainwright Boosts Price Target on CymaBay Therapeutics Inc (CBAY)|
finance.yahoo.com - July 19 at 4:31 AM
|Today's Research Reports on Stocks to Watch: Editas Medicine and Cymabay Therapeutics|
finance.yahoo.com - July 18 at 6:28 PM
|After-Hours Stock Movers 07/17: (NFLX) (PBYI) (NVAX) Higher; (CBAY) (REI) (SCSS) Lower (more...) - StreetInsider.com|
www.streetinsider.com - July 17 at 10:22 PM
|CymaBay Therapeutics (CBAY) Announces 10M Share Common Offering - StreetInsider.com|
www.streetinsider.com - July 17 at 10:22 PM
|Mid-Day Market Update: Sevcon Surges Following Acquisition News; TherapeuticsMD Shares Slide - Benzinga|
www.benzinga.com - July 17 at 5:22 PM
|Health Care Sector Update for 07/17/2017: CBAY,ACRX,RPRX - Nasdaq|
www.nasdaq.com - July 17 at 5:22 PM
|CymaBay Therapeutics (CBAY) Reports Interim Results Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients ... - StreetInsider.com|
www.streetinsider.com - July 17 at 5:22 PM
|Implied Volatility Surging for Cymabay Therapeutics (CBAY) Stock Options - Nasdaq|
www.nasdaq.com - July 13 at 8:50 PM
|Implied Volatility Surging for Cymabay Therapeutics (CBAY) Stock Options|
finance.yahoo.com - July 13 at 3:41 PM
|New Analyst Coverage Make These 5 Stocks Worth a Bet - Nasdaq|
www.nasdaq.com - July 3 at 10:15 PM
|New Analyst Coverage Make These 5 Stocks Worth a Bet|
finance.yahoo.com - July 3 at 5:00 PM
|Short Interest in CymaBay Therapeutics Inc. (NASDAQ:CBAY) Decreases By 32.6%|
www.americanbankingnews.com - July 1 at 7:06 AM
|Penny Stocks to Watch for July 2017|
finance.yahoo.com - June 30 at 5:06 PM
|CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality ... - Nasdaq|
www.nasdaq.com - June 27 at 9:26 PM
CymaBay Therapeutics (CBAY) Chart for Monday, August, 21, 2017